title: Zygomycosis (mucormycosis) and HIV infection: report of three cases and review.
abstract: We report three cases of zygomycosis (mucormycosis) occurring in three individuals infected with the human immunodeficiency virus (HIV) and review 12 other published cases. We present the only two case reports of disseminated zygomycosis in AIDS patients, and the only AIDS patient with renal zygomycosis to survive without nephrectomy, receiving intravenous (i.v.) amphotericin alone. Coinfection with zygomycosis and HIV is rare, occurs primarily in patients with low CD4+ lymphocyte counts, does not always require the usual predisposing conditions for zygomycosis, and may be the presenting opportunistic infection among HIV-infected persons. Transient episodes of neutropenia occurring within 4 months before presentation may be a risk factor for this disease. Zygomycosis may arise in multiple sites including the basal ganglia, cutaneous tissue, kidney, respiratory tract, and may be disseminated. Occurring more commonly in, but not restricted to, injection drug users, it is significantly associated with sites other than basal ganglia in those patients with advanced HIV disease or AIDS. The presenting symptoms are related to the site of involvement, and the illness may develop insidiously or progress rapidly to a fulminant course. Successful therapy usually consists of surgical debridement and intravenous amphotericin B. Overall mortality in this review is 40%, and is significantly associated with sites of disease inaccessible to surgical debridement.
authors.affiliation: Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Nagy-Agren
authors.forename: P
authors.initials: P
authors.lastname: Chu
authors.forename: G J
authors.initials: GJ
authors.lastname: Smith
authors.forename: H A
authors.initials: HA
authors.lastname: Waskin
authors.forename: F L
authors.initials: FL
authors.lastname: Altice
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D005260:Female; D016469:Fungemia / Q000150:complications / Q000175:diagnosis; D006801:Humans; D007410:Intestinal Diseases / Q000150:complications / Q000175:diagnosis; D007421:Intestine, Small / Q000382:microbiology / Q000473:pathology; D007668:Kidney / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D007674:Kidney Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009090:Mucorales / Q000302:isolation & purification; D009091:Mucormycosis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B